For the quarter ending 2025-09-30, LIXT has $5,433,676 in assets.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 2,887,874 | 887,212 | ||
| Prepaid insurance | 29,490 | 14,597 | ||
| Other prepaid expenses | 61,839 | 87,943 | ||
| Digital assets | 2,454,473 | - | ||
| Total current assets | 5,433,676 | 989,752 | ||
| Deferred offering costs | - | 198,826 | ||
| Total assets | 5,433,676 | 1,188,578 | ||
| Accounts payable and accrued expenses, including 112,033 and 27,500 to related parties at september 30, 2025 and december 31, 2024, respectively | 235,900 | 92,149 | ||
| Research and development contract liabilities | 235,155 | 256,147 | ||
| Accrued offering costs | - | 188,826 | ||
| Series b convertible preferred stock 8 cumulative dividend payable | 50,367 | - | ||
| Total current liabilities | 521,422 | 537,122 | ||
| Preferred stock, value-Series BConvertible Preferred Stock | 2,553,359 | - | ||
| Common stock, 0.0001 par value authorized 100,000,000 shares issued and outstanding 5,704,200 and 2,249,290 shares at september 30, 2025 and december 31, 2024 | 570 | 276 | ||
| Additional paid-in capital | 57,891,644 | 54,204,101 | ||
| Accumulated deficit | -55,533,319 | -53,552,921 | ||
| Total stockholders equity | 4,912,254 | 651,456 | ||
| Total liabilities and stockholders equity | 5,433,676 | 1,188,578 | ||
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)